Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

RenovoRx Gelecekteki Büyüme

Future kriter kontrolleri 3/6

RenovoRx kazanç ve gelirinin sırasıyla yıllık 63.9% ve 74.6% oranında artması tahmin edilirken, EPS'nin yıllık 65% oranında büyümesi bekleniyor.

Anahtar bilgiler

63.9%

Kazanç büyüme oranı

65.0%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.9%
Gelir büyüme oranı	74.6%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	12 Sep 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:RNXT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	12	-7	N/A	N/A	2
12/31/2025	N/A	-13	N/A	-9	3
12/31/2024	N/A	-9	N/A	-10	3
6/30/2024	N/A	-8	-9	-9	N/A
3/31/2024	N/A	-8	-10	-10	N/A
12/31/2023	N/A	-10	-10	-10	N/A
9/30/2023	N/A	-9	-10	-10	N/A
6/30/2023	N/A	-10	-10	-10	N/A
3/31/2023	N/A	-10	-9	-9	N/A
12/31/2022	N/A	-10	-9	-9	N/A
9/30/2022	N/A	-10	-10	-10	N/A
6/30/2022	N/A	-9	-8	-8	N/A
3/31/2022	N/A	-8	-7	-7	N/A
12/31/2021	N/A	-6	-6	-6	N/A
9/30/2021	N/A	-5	-4	-4	N/A
6/30/2021	N/A	-4	-4	-4	N/A
3/31/2021	N/A	-4	-3	-3	N/A
12/31/2020	N/A	-4	-4	-4	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RNXT önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.5% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: RNXT önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: RNXT önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: RNXT gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: RNXT gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RNXT 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

RenovoRx Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 29% to US$5.17

Price target increased by 29% to US$5.17

Price target increased by 29% to US$5.17

Price target decreased by 23% to US$8.50

Price target increased by 15% to US$11.50

Price target decreased to US$10.00

Recent updates

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx, Inc. Announces Publication of Positive Early-Stage Clinical Data Relating to its Trans-Arterial Micro-Perfusion Therapy Platform

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

Price target increased by 29% to US$5.17

Price target increased by 29% to US$5.17

Price target increased by 29% to US$5.17

RenovoRx, Inc. Announces Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential

RenovoRx, Inc., Annual General Meeting, Jun 06, 2024

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting

RenovoRx, Inc. announced that it has received $11.136652 million in funding

New major risk - Negative shareholders equity

New major risk - Shareholder dilution

Renovorx, Inc. Announces Demise of David Diamond as Lead Independent Director, Chair of the Audit Committee and Member of the Compensation Committee

Renovorx Engages Oklahoma University Health as First Clinical Site in Preparation for the Pivotal Phase Iiiougar Clinical Trial in Bile Duct Cancer

RenovoRx, Inc. Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform

Renovorx Appoints Michel Ducreux as Scientific Advisory Board

Price target decreased by 23% to US$8.50

RenovoRx Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

RenovoRx, Inc. announced delayed 10-Q filing

RenovoRx, Inc Announces New Positive Interim Phase III Data Demonstrating RenovoGem(TM) Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer

RenovoRx, Inc. Appoints Margaret A.Tempero, M.D., to Scientific Advisory Board

Renovorx, Inc. Initiates Patient Enrollment At University of Texas Southwestern Medical Center for Pivotal Phase III Tiger-Pac Clinical Trial

RenovoRx, Inc. Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?

Price target increased by 15% to US$11.50

Renovorx, Inc. Announces Initial Results from A Pharmacokinetic (PK) Substudy Within the Phase III Un-Blinded Randomized Control Tiger-Pac Clinical Trial

Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky

Price target decreased to US$10.00

RenovoRx, Inc. Appoints Angela Gill Nelms as Chief Operating Officer

RenovoRx reports Q2 results

Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?

Renovorx Appoints James Ahlers as Chief Financial Officer

RenovoRx names new finance CFO

Renovorx Launches "The Renovorx Story" Video Series

RenovoRx, Inc., Annual General Meeting, Jun 09, 2022

RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans

RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University’s New York-Presbyterian Hospital Irving Medical Center in Ongoing Tiger-Pac Phase 3 Clinical Trial

We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth

RenovoRx, Inc. Receives New 510(k) Clearance for its RenovoCath Delivery System Designed for Targeted Treatment of Solid Tumors

RenovoRx, Inc. has completed an IPO in the amount of $16.65 million.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin